UPCOMING SESSIONS in ET
Wed, Apr 8, 2026
10:00 – 11:00 PM UTC
CAR-T Therapy for AL Amyloidosis: What’s New, What’s Real, and What’s Next Heather Landau Click To Register
UPCOMING SESSIONS in ET
Wed, Apr 8, 2026 · 10:00 – 11:00 PM UTC
CAR-T Therapy for AL Amyloidosis: What’s New, What’s Real, and What’s Next
Heather Landau
Click To Register
View all sessions

Evolution of Hematopoietic Cell Transplantation for Immunoglobulin Light Chain Amyloidosis

Published: Oct 21, 2015
Category
Scientific Articles
Key Information
Source
Biology of Blood and Marrow Transplantation
Year
2015
summary/abstract

Immunoglobulin light chain amyloidosis is the most common type of systemic amyloidosis. Hematopoietic stem cell transplantation (HCT) is an effective treatment option for AL however due to multi-organ involvement in this disease HCT is feasible in a minority of patients. To maximize the benefit and minimize toxicity it is of paramount importance to optimize the selection of patients for HCT. In this review we discuss evolution of HCT and its typical application to a case of AL amyloidosis.

Abstract Source
https://www.ncbi.nlm.nih.gov/pubmed/26475727
Full Text Source
https://www.bbmt.org/article/S1083-8791(15)00680-1/fulltext
DOI
10.1016/j.bbmt.2015.10.010
Pubdate
2015
Authors
Sher T, Dispenzieri A, Gertz MA
Organisation
Mayo Clinic, USA

Tags